Repligen
RGEN
#2474
Rank
A$10.73 B
Marketcap
A$190.68
Share price
-0.54%
Change (1 day)
-26.27%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of September 2025 : A$0.97 Billion

According to Repligen 's latest financial reports the company's total debt is A$0.97 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$1.10 B5.6%
2023-12-31A$1.04 B68.09%
2022-12-31A$0.62 B23.1%
2021-12-31A$0.50 B40.97%
2020-12-31A$0.35 B-4.76%
2019-12-31A$0.37 B156.02%
2018-12-31A$0.14 B15.55%
2017-12-31A$0.12 B-3.81%
2016-12-31A$0.13 B
2005-03-31A$0.15 M36.5%
2004-03-31A$0.11 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
A$86.15 B 8,733.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
A$50.51 B 5,079.52%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
A$29.01 B 2,875.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$66.74 B 6,742.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$35.99 M-96.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$0.35 B-63.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
A$0.58 B-39.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
A$0.49 B-49.06%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$0.85 B-12.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
A$3.72 B 281.59%๐Ÿ‡บ๐Ÿ‡ธ USA